FR16C0019I2 - Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep - Google Patents

Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep

Info

Publication number: FR16C0019I2
Authority: FR; France
Prior art keywords: diabetic; disease; renal; pharmaceutically acceptable; heart failure
Prior art date: 2002-01-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR16C0019C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-17

Filing date

2016-05-17

Publication date

2017-12-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23373410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C0019(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-05-17 Application filed by Novartis AG filed Critical Novartis AG

2016-06-24 Publication of FR16C0019I1 publication Critical patent/FR16C0019I1/fr

2017-12-08 Application granted granted Critical

2017-12-08 Publication of FR16C0019I2 publication Critical patent/FR16C0019I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

FR16C0019C 2002-01-17 2016-05-17 Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep Active FR16C0019I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34966002P	2002-01-17	2002-01-17
PCT/EP2003/000415 WO2003059345A1 (fr)	2002-01-17	2003-01-16	Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep

Publications (2)

Publication Number	Publication Date
FR16C0019I1 FR16C0019I1 (fr)	2016-06-24
FR16C0019I2 true FR16C0019I2 (fr)	2017-12-08

Family

ID=23373410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR16C0019C Active FR16C0019I2 (fr)	2002-01-17	2016-05-17	Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep

Country Status (29)

Country	Link
EP (1)	EP1467728B1 (fr)
JP (2)	JP4820056B2 (fr)
KR (2)	KR20100057704A (fr)
CN (2)	CN1615134A (fr)
AT (1)	ATE370732T1 (fr)
AU (1)	AU2003206738C1 (fr)
BE (1)	BE2016C025I2 (fr)
BR (2)	BR122018015003B8 (fr)
CA (1)	CA2472399C (fr)
CO (1)	CO5600999A2 (fr)
CY (2)	CY1106959T1 (fr)
DE (1)	DE60315795T2 (fr)
DK (1)	DK1467728T3 (fr)
EC (1)	ECSP045190A (fr)
ES (1)	ES2290429T3 (fr)
FR (1)	FR16C0019I2 (fr)
HU (1)	HUS1600024I1 (fr)
IL (2)	IL162661A0 (fr)
LU (1)	LU93074I2 (fr)
MX (1)	MXPA04006917A (fr)
NL (1)	NL300811I2 (fr)
NO (2)	NO333191B1 (fr)
NZ (1)	NZ533968A (fr)
PL (1)	PL212318B1 (fr)
PT (1)	PT1467728E (fr)
RU (1)	RU2334513C3 (fr)
SI (1)	SI1467728T1 (fr)
WO (1)	WO2003059345A1 (fr)
ZA (1)	ZA200405117B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006000564A1 (fr) *	2004-06-23	2006-01-05	Solvay Pharmaceuticals Gmbh	Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at1
DK2033629T3 (da)	2004-12-24	2013-02-04	Krka	Fast farmaceutisk sammensætning omfattende valsartan
MY146830A (en) *	2005-02-11	2012-09-28	Novartis Ag	Combination of organic compounds
WO2007045663A2 (fr) *	2005-10-19	2007-04-26	Novartis Ag	Combinaison de composes organiques
WO2007051007A2 (fr) *	2005-10-28	2007-05-03	Novartis Ag	Combinaison de composes organiques
AR057882A1 (es) *	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (fr) *	2006-03-10	2007-09-20	Novartis Ag	Combinaison de composes organiques
CZ300801B6 (cs) *	2006-06-07	2009-08-12	Helvetia Pharma A.S.	Kompozice s valsartanem v pevných lékových formách
SG185318A1 (en)	2007-01-12	2012-11-29	Novartis Ag	Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
GB0708507D0 (en)	2007-05-02	2007-06-13	Queen Mary & Westfield College	Substituted phosphonates and their use
WO2009061713A1 (fr) *	2007-11-06	2009-05-14	Novartis Ag	Compositions pharmaceutiques
CN101774941A (zh)	2009-01-13	2010-07-14	浙江九洲药业股份有限公司	2-酰基氨基-3-联苯基丙酸的制备及拆分方法
BRPI1011657A2 (pt)	2009-05-28	2019-04-16	Novartis Ag	derivados aminopropiônicos substituídos como inibidores de neprilisina
EP2435402B1 (fr)	2009-05-28	2016-04-13	Novartis AG	Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2576179T3 (es)	2010-08-23	2016-07-06	Novartis Ag	Proceso para la preparación de intermediarios para la elaboración de inhibidores de NEP
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
EP3943084A1 (fr)	2012-08-24	2022-01-26	Novartis AG	Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
KR20150119107A (ko)	2013-02-14	2015-10-23	노파르티스 아게	개선된 생체내 효능을 갖는 nep 억제제로서의 치환된 비스페닐 부탄산 유도체
SG11201506018PA (en)	2013-02-14	2015-08-28	Novartis Ag	Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CN104230865B (zh) *	2013-06-13	2018-01-09	上海翰森生物医药科技有限公司	联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
HUE047186T2 (hu)	2013-08-26	2020-04-28	Novartis Ag	Új alkalmazás
WO2015030711A1 (fr)	2013-08-26	2015-03-05	Novartis Ag	Nouvelle utilisation
WO2016029828A1 (fr) *	2014-08-27	2016-03-03	上海翰森生物医药科技有限公司	Acide crystallin libre, sel hemicalcique et sel d'alpha-phényléthylamine de ahu-377 et son procédé de préparation et son application
WO2016037098A1 (fr) *	2014-09-04	2016-03-10	Concert Pharmaceuticals, Inc.	Sacubitril deutérisé
WO2016037552A1 (fr) *	2014-09-09	2016-03-17	上海翰森生物医药科技有限公司	Composé cristallin bloqueur de récepteur de l'angiotensine-inhibiteur d'endopeptidase neutre (arb-nepi), son procédé de préparation et son application
CN105503760A (zh) *	2014-10-10	2016-04-20	上海翰森生物医药科技有限公司	结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
WO2016074651A1 (fr)	2014-11-14	2016-05-19	Zentiva, K.S.	Procédé de préparation, d'isolation et de purification de formes pharmaceutiquement applicables de ahu-377
WO2016086798A1 (fr) *	2014-12-03	2016-06-09	上海翰森生物医药科技有限公司	Acide libre cristallin d'inhibiteur de l'endopeptidase neutre (nep), polymorphe de sel de calcium de celui-ci, leur procédé de préparation et leurs applications
CN110938042B (zh) *	2014-12-08	2022-12-13	苏州晶云药物科技股份有限公司	一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
CN105693543B (zh) *	2014-12-15	2018-08-10	四川海思科制药有限公司	沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104826115A (zh) *	2015-04-19	2015-08-12	浙江巨泰药业有限公司	一种抗心衰药物组合物及其制备方法
CN106138069A (zh) *	2015-04-21	2016-11-23	刘春丽	作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷
HUE071910T2 (hu)	2015-05-11	2025-10-28	Novartis Ag	Szakubitril-valzartán adagolási rend krónikus szisztolés szívelégtelenség kezelésére
US20180140579A1 (en)	2015-05-29	2018-05-24	Novartis Ag	Sacubitril and valsartan for treating metabolic disease
WO2017006254A1 (fr)	2015-07-08	2017-01-12	Novartis Ag	Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
WO2017012600A1 (fr)	2015-07-20	2017-01-26	Zentiva, K.S.	Composition pharmaceutique contenant du valsartan et du sacubitril et procédés de préparation et de stabilisation correspondants
CN106397248A (zh) *	2015-08-03	2017-02-15	深圳信立泰药业股份有限公司	一种lcz696结晶粉末及其制备方法
WO2017037577A1 (fr)	2015-08-28	2017-03-09	Novartis Ag	Nouvelle utilisation
WO2017036420A1 (fr) *	2015-09-06	2017-03-09	常州方楠医药技术有限公司	Composition pharmaceutique contenant du valsartan et du sacubitril, et procédé de préparation associé
CN105348209B (zh)	2015-12-09	2017-12-26	浙江天宇药业股份有限公司	一种抗心衰药lcz696的制备方法
MX2018007129A (es)	2015-12-11	2018-11-09	Zentiva Ks	Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
HK1256865A1 (zh)	2016-02-03	2019-10-04	Novartis Ag	有机化合物的盖伦制剂
EP3411018A1 (fr)	2016-02-03	2018-12-12	Novartis AG	Formes pharmaceutiques à base de composés organiques
DK3524250T3 (da)	2016-10-08	2025-09-08	Wuhan Ll Science & Technology Development Co Ltd	Farmaceutisk sammensætning, som omfatter en neutral endopeptidase (nep)-inhibitor og et azilsartan ester-derivat og anvendelse deraf til behandling af hjerte-kar-sygdomme
WO2018211479A1 (fr)	2017-05-19	2018-11-22	Lupin Limited	Compositions stabilisées d'inhibiteurs de l'angiotensine ii et d'inhibiteurs de l'endopeptidase neutre, et leur procédé de préparation
US11382866B2 (en)	2017-07-06	2022-07-12	Mankind Pharma Ltd.	Fixed dose pharmaceutical composition of valsartan and sacubitril
ES2881317T3 (es)	2017-07-28	2021-11-29	Synthon Bv	Composición farmacéutica que comprende sacubitrilo y valsartán
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN110237071B (zh)	2018-03-09	2022-03-22	武汉朗来科技发展有限公司	药物制剂及其应用
WO2020039386A1 (fr)	2018-08-23	2020-02-27	Novartis Ag	Nouvelle utilisation pharmaceutique pour le traitement d'une insuffisance cardiaque
WO2020039394A1 (fr)	2018-08-24	2020-02-27	Novartis Ag	Nouvelles combinaisons de médicaments
WO2021158084A1 (fr) *	2020-02-07	2021-08-12	보령제약 주식회사	Composé hybride et son procédé de préparation
KR20210101164A (ko)	2020-02-07	2021-08-18	보령제약 주식회사	하이브리드 화합물 및 그 제조방법
KR20200020746A (ko)	2020-02-07	2020-02-26	보령제약 주식회사	하이브리드 화합물 및 그 제조방법
KR20210120560A (ko)	2020-03-27	2021-10-07	주식회사 유영제약	고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20220091767A (ko)	2020-12-24	2022-07-01	주식회사 보령	사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
WO2024136184A1 (fr)	2022-12-20	2024-06-27	주식회사 티에치팜	Préparation pharmaceutique orale comprenant un inhibiteur du cotransporteur de sodium-glucose de type 2 et un bloqueur du récepteur de l'angiotensine ii
WO2024136185A1 (fr)	2022-12-20	2024-06-27	주식회사 티에치팜	Composition pharmaceutique pour la prévention ou le traitement d'une maladie cardiovasculaire, comprenant un inhibiteur du cotransporteur sodium-glucose-2 et un bloqueur du récepteur de l'angiotensine ii

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1256692A (en) *	1991-02-06	1992-09-07	Schering Corporation	Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) *	1992-01-22	1993-06-08	Ciba-Geigy Corporation	Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (fr) *	1995-02-08	1996-08-09	James R. Powell	Traitement de l'hypertension et de l'insuffisance cardiaque globale
AU2001287289A1 (en) *	2000-04-03	2001-10-15	Bristol-Myers Squibb Company	Vasopeptidase inhibitors to treat isolated systolic hypertensions
HUP0301390A3 (en) *	2000-06-22	2005-04-28	Novartis Ag	Oral pharmaceutical composition containing valsartan
US20030207930A1 (en) *	2000-07-19	2003-11-06	Erwin Marti	Valsartan salts
US6777443B2 (en) *	2001-05-15	2004-08-17	Novartis Ag	Dipeptide derivatives

2003
- 2003-01-16 ES ES03704413T patent/ES2290429T3/es not_active Expired - Lifetime
- 2003-01-16 BR BR122018015003A patent/BR122018015003B8/pt not_active IP Right Cessation
- 2003-01-16 RU RU2004125178A patent/RU2334513C3/ru active
- 2003-01-16 CN CNA038022680A patent/CN1615134A/zh active Pending
- 2003-01-16 CA CA2472399A patent/CA2472399C/fr not_active Expired - Lifetime
- 2003-01-16 AT AT03704413T patent/ATE370732T1/de active
- 2003-01-16 EP EP03704413A patent/EP1467728B1/fr not_active Expired - Lifetime
- 2003-01-16 KR KR1020107010521A patent/KR20100057704A/ko not_active Ceased
- 2003-01-16 PT PT03704413T patent/PT1467728E/pt unknown
- 2003-01-16 SI SI200331029T patent/SI1467728T1/sl unknown
- 2003-01-16 NZ NZ533968A patent/NZ533968A/en not_active IP Right Cessation
- 2003-01-16 BR BRPI0306907A patent/BRPI0306907B8/pt active IP Right Grant
- 2003-01-16 CN CN201110029600.7A patent/CN102091330B/zh not_active Expired - Lifetime
- 2003-01-16 MX MXPA04006917A patent/MXPA04006917A/es active IP Right Grant
- 2003-01-16 KR KR1020047011124A patent/KR100984939B1/ko not_active Ceased
- 2003-01-16 DK DK03704413T patent/DK1467728T3/da active
- 2003-01-16 WO PCT/EP2003/000415 patent/WO2003059345A1/fr not_active Ceased
- 2003-01-16 AU AU2003206738A patent/AU2003206738C1/en active Active
- 2003-01-16 PL PL369773A patent/PL212318B1/pl unknown
- 2003-01-16 JP JP2003559507A patent/JP4820056B2/ja not_active Expired - Lifetime
- 2003-01-16 IL IL16266103A patent/IL162661A0/xx unknown
- 2003-01-16 DE DE60315795T patent/DE60315795T2/de not_active Expired - Lifetime
2004
- 2004-06-21 IL IL162661A patent/IL162661A/en active Protection Beyond IP Right Term
- 2004-06-28 ZA ZA2004/05117A patent/ZA200405117B/en unknown
- 2004-07-14 EC EC2004005190A patent/ECSP045190A/es unknown
- 2004-08-06 CO CO04076723A patent/CO5600999A2/es active IP Right Grant
- 2004-08-13 NO NO20043380A patent/NO333191B1/no not_active IP Right Cessation
2007
- 2007-10-25 CY CY20071101386T patent/CY1106959T1/el unknown
2011
- 2011-05-25 JP JP2011116928A patent/JP2011207898A/ja not_active Withdrawn
2016
- 2016-05-17 FR FR16C0019C patent/FR16C0019I2/fr active Active
- 2016-05-18 LU LU93074C patent/LU93074I2/fr unknown
- 2016-05-18 HU HUS1600024C patent/HUS1600024I1/hu unknown
- 2016-05-18 BE BE2016C025C patent/BE2016C025I2/nl unknown
- 2016-05-18 NL NL300811C patent/NL300811I2/nl unknown
- 2016-05-18 CY CY2016013C patent/CY2016013I2/el unknown
- 2016-05-18 NO NO2016009C patent/NO2016009I1/no unknown

Also Published As

Publication number	Publication date
PT1467728E (pt)	2007-11-14
KR20100057704A (ko)	2010-05-31
CO5600999A2 (es)	2006-01-31
ATE370732T1 (de)	2007-09-15
NO2016009I2 (no)	2016-05-18
CY2016013I1 (el)	2016-10-05
LU93074I2 (fr)	2016-07-18
BR122018015003B1 (pt)	2018-11-21
RU2004125178A (ru)	2005-06-10
SI1467728T1 (sl)	2008-02-29
AU2003206738B2 (en)	2006-12-21
CN102091330A (zh)	2011-06-15
PL369773A1 (en)	2005-05-02
CA2472399C (fr)	2012-02-21
ECSP045190A (es)	2004-08-27
CN1615134A (zh)	2005-05-11
PL212318B1 (pl)	2012-09-28
IL162661A0 (en)	2005-11-20
AU2003206738C1 (en)	2020-01-30
NO333191B1 (no)	2013-03-25
EP1467728B1 (fr)	2007-08-22
BE2016C025I2 (fr)	2022-05-17
BR0306907A (pt)	2004-12-21
CY1106959T1 (el)	2012-01-25
RU2334513C3 (ru)	2017-10-24
DK1467728T3 (da)	2007-12-27
EP1467728A1 (fr)	2004-10-20
FR16C0019I1 (fr)	2016-06-24
NO20043380L (no)	2004-10-07
JP4820056B2 (ja)	2011-11-24
BR122018015003B8 (pt)	2021-07-27
NL300811I2 (fr)	2016-07-27
DE60315795D1 (de)	2007-10-04
WO2003059345A1 (fr)	2003-07-24
IL162661A (en)	2010-11-30
KR20040078127A (ko)	2004-09-08
JP2011207898A (ja)	2011-10-20
NO2016009I1 (no)	2016-05-18
JP2005514441A (ja)	2005-05-19
ZA200405117B (en)	2005-08-31
KR100984939B1 (ko)	2010-10-01
MXPA04006917A (es)	2004-12-06
CA2472399A1 (fr)	2003-07-24
BRPI0306907B1 (pt)	2018-10-30
BRPI0306907B8 (pt)	2021-05-25
RU2334513C2 (ru)	2008-09-27
AU2003206738A1 (en)	2003-07-30
CN102091330B (zh)	2015-04-08
ES2290429T3 (es)	2008-02-16
CY2016013I2 (el)	2016-10-05
KR100984939B9 (ko)	2024-07-17
DE60315795T2 (de)	2008-06-05
HUS1600024I1 (hu)	2016-06-28
NZ533968A (en)	2006-10-27